Talzenna (talazoparib) — Medica
metastatic castration-resistant prostate cancer
Initial criteria
- age ≥ 18 years
- patient has metastatic castration-resistant prostate cancer
- ONE of the following: medication used concurrently with a gonadotropin-releasing hormone (GnRH) analog OR patient has had a bilateral orchiectomy
- patient has homologous recombination repair (HRR) gene-mutated disease (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C)
- medication is used in combination with Xtandi (enzalutamide)
Approval duration
1 year